Hematology / Oncology CE Activities

Hematology / oncology blog

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.

Hematology / Oncology
Blog

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).

Hematology / Oncology
Blog

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.

Hematology / Oncology
Blog

RMEI Presentations

Answering the Call to Action: How Nurses Have Become Progressively More Involved in Immunotherapy IME (2018 to Present)

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.

Hematology / Oncology
Decision Support Aid

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.

Hematology / Oncology
Decision Support Aid

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

Latest Hematology / Oncology Articles

A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? July 23, 2026
For more than two decades, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy has been the standard of care for muscle-invasive bladder cancer. Despite this approach, relapse rates have remained high and long-term survival gains have been modest. The treatment landscape began to shift with the NIAGARA trial, which showed a...
Srikala S. Sridhar
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer July 23, 2026
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy.
Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin, the RASolute 302 Trial Investigators*
Breaking the RAS Barrier in Pancreatic Cancer July 23, 2026
For decades, pancreatic ductal adenocarcinoma (PDAC) has been perhaps the clearest example of a cancer that is driven by a dominant oncogenic event yet is resistant to therapeutic exploitation. More than 90% of pancreatic cancers harbor activating RAS mutations, most commonly those involving KRAS codon 12,...
Shivan Sivakumar

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.